Contraception
News from the FDA/CDC
FDA approves first over-the-counter birth control pill
The product, OPill, is expected to be available early in 2024.
From the Journals
Do oral contraceptives increase depression risk?
The authors also didn’t study the indication for OC use. Several medical conditions are treated with OCs, including premenstrual dysphoric...
Conference Coverage
Youth-led sexual health program improves teen knowledge, autonomy
Participants in the 9-month program improved in all domains assessed, including sexual and reproductive health knowledge, self-efficacy and...
Conference Coverage
Scheduled bleeding may boost tolerability of hormone implants
Rates of early discontinuation have been variable, according to published literature, ranging from 13% to 21.1%, said Dr. Jordan Gray.
Commentary
Neuropsychiatric side effects of hormonal contraceptives: More common than you think!
Practitioners of all types need to engage in shared decision-making to identify the key benefits and risks of hormonal contraceptive use for each...
From the Journals
Adherence to oral contraceptive protocols prevents pregnancy
Pregnancy rates rise when oral contraceptive users miss more than two pills or fail to follow instructions.
Latest News
Frustration over iPLEDGE evident at FDA meeting
Dermatologists argue the iPLEDGE REMS burden is too high for providers and patients. Access problems persist with lockouts and some cite a lack of...
Latest News
FDA Advisory panels consider easing isotretinoin requirements
The 2-day meeting is addressing what can be done to reduce burden with the iPLEDGE REMS while maintaining safety and preventing fetal exposure to...
Latest News
Risk of expulsion low after early postpartum IUD placement
The early postpartum period 2-4 weeks after birth has the advantage of convenience since it coincides with early-postpartum or well-baby visits....
Latest News
Ectopic pregnancy risk and levonorgestrel-releasing IUDs
The hormone content in levonorgestrel-releasing IUDs must be high enough to maintain optimal contraceptive effect but sufficiently low to minimize...
PURLs
Is self-administered DMPA an answer to contraception access in the post-Roe era?
Compared with provider-administered depot medroxyprogesterone acetate, a prefilled formulation may offer patients improved access to effective...